Prostate Cancer

Modeling Agent

N-Nitroso-N-methylurea

Drugs Approved

Olaparib

Enzalutamide

Talazoparib

Docetaxel

Niraparib tosylate

Darolutamide

Apalutamide 

Abiraterone Acetate

Mitoxantrone 2HCl

Cabazitaxel

Bicalutamide

Flutamide

Relugolix

Rucaparib Camsylate

Degarelix acetate

Nilutamide

Endocrine Therapy ^[1]

AR

Enzalutamide

Darolutamide

Apalutamide 

Bavdegalutamide

GnRHR

Relugolix

Degarelix acetate

Abarelix

CYP17A1

Abiraterone

Galeterone

Orteronel

Targeting Bone Microenvironment

Bisphosphonates

Zoledronic acid

Risedronate

Alendronic Acid

Clodronate disodium tetrahydrate

RANKL

Denosumab

Calcium Channels ^[2]

Thapsigargin

GSK1016790A

Suramin sodium salt

ML-9 HCl

SKF96365

CarboxyaMidotriazole orotate

Diethylstilbestrol

5-BDBD

Chemotherapy

Docetaxel

Carboplatin

Mitoxantrone 2HCl

Cabazitaxel

Estramustine phosphate sodium

ICIs

PD-1

Pembrolizumab

Nivolumab

PD-L1

Atezolizumab

Durvalumab

Avelumab

CTLA4

Ipilimumab

Anti-Angiogenesis ^[3]

Bevacizumab

Sorafenib

Sunitinib

Thalidomide

Cabozantinib

Cediranib

Lenalidomide

Tasquinimod

Carotuximab

Targeting PSMA ^[1]

mAbs

Rosopatamab

Pelgifatamab

ADC

Vipivotide tetraxetan

Targeting DNA Repair ^[1]

PARP

Olaparib

Talazoparib

Niraparib

Veliparib

Rucaparib

Pamiparib

Targeting Cell Cycle ^[1]

CDK4/6

Abemaciclib

Ribociclib

Palbociclib

Mutant p53

Eprenetapopt

Targeting PI3K/AKT/mTOR ^[1]

PI3K

Dactolisib

Samotolisib

AZD8186

GSK2636771

AKT

Perifosine

MK-2206 2HCl

Ipatasertib

Capivasertib

mTOR

Rapamycin

Ridaforolimus

Temsirolimus

Everolimus

Sapanisertib

Vistusertib

CC-115

PI3K/mTOR

Apitolisib

Targeting Epigenetic Marks ^[1]

EZH2

Lirametostat

PF-06821497

Tazemetostat

Valemetostat

LSD1

Pulrodemstat besylate

p300/CBP

Inobrodib

BET bromodomain

Birabresib

Mivebresib

Molibresib

ZEN-3694

HDACs

Entinostat

Panobinostat

Pracinostat

Vorinostat

DNMT

Azacitidine

Decitabine

Targeting WNT signaling ^[1]

WNT-5A

Foxy-5

VEGF-A

Bevacizumab

ETAR

Zibotentan

FGFR

Erdafitinib

Masitinib

EGFR

Cetuximab

Gefitinib

VEGFR

Sunitinib

Cabozantinib

TGFβR1

Galunisertib

Anti-TGFb1

SRC

Dasatinib

Saracatinib

MEK

Trametinib

Compound Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Tyrosine Kinase Inhibitor Library

PI3K/Akt Inhibitor Library